TY - JOUR
T1 - Diagnosis and classification of blepharospasm
T2 - Recommendations based on empirical evidence
AU - for the Dystonia Coalition Investigators
AU - Kilic-Berkmen, Gamze
AU - Defazio, Giovanni
AU - Hallett, Mark
AU - Berardelli, Alfredo
AU - Ferrazzano, Gina
AU - Belvisi, Daniele
AU - Klein, Christine
AU - Bäumer, Tobias
AU - Weissbach, Anne
AU - Perlmutter, Joel S.
AU - Feuerstein, Jeanne
AU - Jinnah, H. A.
N1 - Funding Information:
HAJ has active or recent grant support from the US government (National Institutes of Health), private philanthropic organizations (Cure Dystonia Now), and industry (Revance Therapeutics, Inc.). Dr. Jinnah has also served on advisory boards or as a consultant for Addex, Allergan, CoA Therapeutics, Cavion Therapeutics, EnePharmaceuticals, Ipsen, Retrophin, Revance, and Takaha Pharmaceuticals. He has received honoraria or stipends for lectures or administrative work from the International Parkinson's Disease and Movement Disorders Society. Dr. Jinnah serves on the Scientific Advisory Boards for several private foundations including the Benign Essential Blepharospasm Research Foundation, Cure Dystonia Now, the Dystonia Medical Research Foundation, the Tourette Association of America, and Tyler's Hope for a Cure. He also is principle investigator for the Dystonia Coalition, which has received the majority of its support through the NIH (grants NS116025, NS065701 from the National Institutes of Neurological Disorders and Stroke and TR001456 from the Office of Rare Diseases Research at the National Center for Advancing Translational Sciences). The Dystonia Coalition has received additional material or administrative support from industry sponsors (Allergan Inc. and Merz Pharmaceuticals) as well as private foundations (The Benign Essential Blepharospasm Foundation, Cure Dystonia Now, The Dystonia Medical Research Foundation, and The National Spasmodic Dysphonia Association).JSP was supported by NIH (NINDS/NIA) NS075321, the American Parkinson's disease Association (APDA), the Greater St. Louis Chapter of the APDA, the Barnes Jewish Hospital Foundation (Elliot Stein Family Fund), the Oertli Fund, the Murphy Fund, the Paula and Rodger Riney Fund, and N Grant Williams Fund.MH is supported by the NINDS Intramural Program.This work was supported by grants to The Dystonia Coalition (NS065701, TR001456, NS116025) which is part of the National Institutes of Health (NIH) Rare Disease Clinical Research Network (RDCRN), supported by the Office of Rare Diseases Research (ORDR) at the National Center for Advancing Translational Science (NCATS), and the National Institute of Neurological Diseases and Stroke (NINDS).
Funding Information:
TB is an employee of the University Hospital Schleswig Holstein. He received speaker and consultant fees from Pelzerhaken Children's Centre, Allergan/Abbvie, Ipsen Pharma and Merz Pharmaceuticals. He has received research funding from: German Research Foundation (FG 2698 and SFB 936) and Ipsen Pharma. He was supported with exhibition ultrasound equipment on loan from Cannon and ESAOTE.
Funding Information:
JSP was supported by NIH (NINDS/NIA) NS075321, the American Parkinson's disease Association (APDA), the Greater St. Louis Chapter of the APDA, the Barnes Jewish Hospital Foundation (Elliot Stein Family Fund), the Oertli Fund, the Murphy Fund, the Paula and Rodger Riney Fund, and N Grant Williams Fund.
Funding Information:
HAJ has active or recent grant support from the US government ( National Institutes of Health ), private philanthropic organizations (Cure Dystonia Now), and industry (Revance Therapeutics, Inc.). Dr. Jinnah has also served on advisory boards or as a consultant for Addex, Allergan, CoA Therapeutics, Cavion Therapeutics, EnePharmaceuticals, Ipsen, Retrophin, Revance, and Takaha Pharmaceuticals. He has received honoraria or stipends for lectures or administrative work from the International Parkinson's Disease and Movement Disorders Society. Dr. Jinnah serves on the Scientific Advisory Boards for several private foundations including the Benign Essential Blepharospasm Research Foundation, Cure Dystonia Now, the Dystonia Medical Research Foundation, the Tourette Association of America, and Tyler's Hope for a Cure. He also is principle investigator for the Dystonia Coalition, which has received the majority of its support through the NIH (grants NS116025, NS065701 from the National Institutes of Neurological Disorders and Stroke and TR001456 from the Office of Rare Diseases Research at the National Center for Advancing Translational Sciences). The Dystonia Coalition has received additional material or administrative support from industry sponsors (Allergan Inc. and Merz Pharmaceuticals) as well as private foundations (The Benign Essential Blepharospasm Foundation, Cure Dystonia Now, The Dystonia Medical Research Foundation, and The National Spasmodic Dysphonia Association).
Funding Information:
AW has received funding from the Else Kröner-Fresenius foundation (EKFS, 2018_A55) and the German Research Foundation (DFG, WE5919/2–1).
Funding Information:
This work was supported by grants to The Dystonia Coalition ( NS065701 , TR001456 , NS116025 ) which is part of the National Institutes of Health (NIH) Rare Disease Clinical Research Network (RDCRN), supported by the Office of Rare Diseases Research (ORDR) at the National Center for Advancing Translational Science (NCATS) , and the National Institute of Neurological Diseases and Stroke (NINDS) .
Publisher Copyright:
© 2022
PY - 2022/8/15
Y1 - 2022/8/15
N2 - Background: Blepharospasm is one of the most common subtypes of dystonia, and often spreads to other body regions. Despite published guidelines, the approach to diagnosis and classification of affected body regions varies among clinicians. Objective: To delineate the clinical features used by movement disorder specialists in the diagnosis and classification of blepharospasm according to body regions affected, and to develop recommendations for a more consistent approach. Methods: Cross-sectional data for subjects diagnosed with all types of isolated dystonia were acquired from the Dystonia Coalition, an international, multicenter collaborative research network. Data were evaluated to determine how examinations recorded by movement disorder specialists were used to classify blepharospasm as focal, segmental, or multifocal. Results: Among all 3222 participants with isolated dystonia, 210 (6.5%) had a diagnosis of focal blepharospasm. Among these 210 participants, 34 (16.2%) had dystonia outside of upper face region. Factors such as dystonia severity across different body regions and number of body regions affected influenced the classification of blepharospasm as focal, segmental, or multifocal. Conclusions: Although focal blepharospasm is the second most common type of dystonia, a high percentage of individuals given this diagnosis had dystonia outside of the eye/upper face region. These findings are not consistent with existing guidelines for the diagnosis and classification of focal blepharospasm, and point to the need for more specific guidelines for more consistent application of existing recommendations for diagnosis and classification.
AB - Background: Blepharospasm is one of the most common subtypes of dystonia, and often spreads to other body regions. Despite published guidelines, the approach to diagnosis and classification of affected body regions varies among clinicians. Objective: To delineate the clinical features used by movement disorder specialists in the diagnosis and classification of blepharospasm according to body regions affected, and to develop recommendations for a more consistent approach. Methods: Cross-sectional data for subjects diagnosed with all types of isolated dystonia were acquired from the Dystonia Coalition, an international, multicenter collaborative research network. Data were evaluated to determine how examinations recorded by movement disorder specialists were used to classify blepharospasm as focal, segmental, or multifocal. Results: Among all 3222 participants with isolated dystonia, 210 (6.5%) had a diagnosis of focal blepharospasm. Among these 210 participants, 34 (16.2%) had dystonia outside of upper face region. Factors such as dystonia severity across different body regions and number of body regions affected influenced the classification of blepharospasm as focal, segmental, or multifocal. Conclusions: Although focal blepharospasm is the second most common type of dystonia, a high percentage of individuals given this diagnosis had dystonia outside of the eye/upper face region. These findings are not consistent with existing guidelines for the diagnosis and classification of focal blepharospasm, and point to the need for more specific guidelines for more consistent application of existing recommendations for diagnosis and classification.
KW - Blepharospasm
KW - Craniofacial dystonia
KW - Meige syndrome
UR - http://www.scopus.com/inward/record.url?scp=85132366645&partnerID=8YFLogxK
U2 - 10.1016/j.jns.2022.120319
DO - 10.1016/j.jns.2022.120319
M3 - Article
C2 - 35716653
AN - SCOPUS:85132366645
SN - 0022-510X
VL - 439
JO - Journal of the Neurological Sciences
JF - Journal of the Neurological Sciences
M1 - 120319
ER -